Business Wire

TXOne Networks Introduces Breakthrough Capability for Intelligent Vulnerability Mitigation in New Release of TXOne SageOne

4.6.2025 04:00:00 CEST | Business Wire | Press Release

Share

TXOne Networks, a leader in Cyber-Physical Systems (CPS) security, today announced an expanded new version of its SageOne OT Cybersecurity Governance Platform. Already relied upon by many industrial leaders across sectors with exacting cybersecurity requirements, TXOne SageOne has been enhanced to deliver a novel capability for intelligent vulnerability mitigation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603632277/en/

One of the most common challenges faced by (operational technology) OT cybersecurity practitioners is how to patch effectively under time constraints—making risk-based prioritization essential. TXOne SageOne uniquely integrates external intelligence on emerging threats, the specific operational context of each manufacturer and industry-standard vulnerability scoring to provide meaningful, tailored guidance to the organization’s security team. The TXOne Networks solution implements a rigorous, three-phase approach to risk-based vulnerability management:

  • Assess—TXOne SageOne pulls deep, OS-level vulnerability and configuration data—augmented by real-time threat intelligence—to build an accurate, context-rich view of every CPS asset’s true risk exposure.
  • Prioritize—Asset criticality, observed attack patterns and existing defenses are fused into TXOne Networks’ proprietary Vulnerability Situational Awareness Rating (VSAR) risk score to distill thousands of potential flaws to the few that truly demand attention.
  • Remediate—TXOne SageOne automatically interprets each asset’s context (device type, operational status and business impact) and prescribes the optimal mitigation path (full patching, virtual patching or just-In-time guided micro-segmentation) without disrupting production.

CPS consist of mission-critical assets and sophisticated computation and shutting down a production line to implement a patch on such a system or to undertake other protective measures in the OT network generally is not an option. Conventional cybersecurity management platforms rely on vulnerability scoring that is predicated on concepts and protocols borrowed from information technology (IT). That information is useful in OT cybersecurity—but impractical if relied upon alone. Conventional systems often indicate thousands of high-priority vulnerabilities across a large-scale manufacturing environment. A security team tasked with securing OT often is no more than 10 people, so the practical reality is the majority of alerts generated by today’s conventional systems go unaddressed.

TXOne SageOne, however, narrows guidance to a manageable number of legitimately critical vulnerabilities that demand immediate action across a given manufacturer’s OT threat landscape. Armed with a holistic, dependable overview of the truly urgent threats to its corporate environment, the security team is positioned to immediately take concrete, meaningful steps to protect people, OT assets and processes.

“TXOne SageOne represents a breakthrough in OT security governance, having been conceived and purpose-built from the ground up to address the unique cybersecurity needs of OT networks and systems—not IT,” said Dr. Terence Liu, CEO of TXOne Networks. “The latest release introduces intelligent vulnerability mitigation capabilities that underscore this differentiation, empowering security teams with tools tailored to the specific nature of OT environments and delivering actionable insights that lead to achievable, impactful outcomes.”

All of TXOne Networks’ industry-leading point products for CPS security are centrally controlled via the SageOne platform—Stellar for endpoint protection, Element for security inspection and Edge for network defense. As the central hub for all TXOne Networks security offerings, SageOne brings Element, Stellar, and Edge into seamless collaboration to deliver unified visibility, centralized control and optimized vulnerability management. TXOne SageOne provides a comprehensive, detailed and easy-to-understand visualization of the precise security posture of operations at any given moment.

For more information on TXOne SageOne, please visit https://www.txone.com/products/cps-protection-platform/txone-sageone/.

Follow TXOne Networks on Blog, Twitter, and LinkedIn.

About TXOne Networks

TXOne Networks offers cybersecurity solutions that ensure the reliability and safety of industrial control systems and operational technology environments. TXOne Networks works together with both leading manufacturers and critical infrastructure operators to develop practical, operations-friendly approaches to cyber defense. TXOne Networks offers both network-based and endpoint-based products to secure the OT network and mission-critical devices using a real-time, defense-in-depth approach. www.txone.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20250603632277/en/

Contacts

Global Media Contacts

Lynette Lee
lynette.lee@txone.com

Minu Seshasayee
Interprose for TXOne Networks Americas
minu_seshasayee@interprosepr.com
+1 425.283.7426

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press Release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press Release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press Release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press Release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press Release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye